Table 2.
Serum metabolites quantified to be altered in sarcoidosis patients as compared with healthy controls
| Metabolite | Peak regions (ppm) | Change | p value | KEGG No. |
|---|---|---|---|---|
| (A) | ||||
| 3-Hydroxybutyrate | 1.2, 2.3, 2.4, 4.1 | ↑ | 0.005 | C01089 |
| Acetoacetate | 2.3,3.4 | ↑ | 0.011 | C00164 |
| Carnitine | 2.4, 3.2, 3.4, 4.6 | ↑↑ | 0.002 | C00318 |
| Cystine | 3.2, 3.4, 4.1 | ↑↑ | 0.000 | C00491 |
| Homocysteine | 2.1,2.2,2.6,2.7,3.9 | ↑↑ | 0.000 | C00155 |
| Pyruvate | 2.4 | ↑ | 0.006 | C00022 |
| Trimethylamine-N-oxide | 3.3 | ↑↑ | 0.001 | C01104 |
| (B) | ||||
| Glutamine | 2.1,2.2,2.4,2.5,3.8,6.9,7.6 | ↓↓ | 0.002 | C00064 |
| Isoleucine | 0.9,1.0,1.2, 1.5, 2.0,3.7 | ↓↓ | 0.003 | C00407 |
| Succinate | 2.4 | ↓↓ | 0.002 | C00042 |
Serum metabolites found to be significantly higher (A) or lower (B) in sarcoidosis patients, as compared with healthy controls. The metabolites were quantified using the Chenomx 7.6 NMR Suite database and significance was obtained using the Independent Sample T-test, SPSS, p < 0.05